Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Large B-Cell, Diffuse 60Lymphoma 57Lymphoma, Non-Hodgkin 54Lymphoma, Follicular 43Lymphoma, Mantle-Cell 31Lymphoma, B-Cell, Marginal Zone 26Lymphoma, B-Cell 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Burkitt Lymphoma 19Waldenstrom Macroglobulinemia 16Recurrence 16Hodgkin Disease 13Multiple Myeloma 9Lymphoma, Large-Cell, Immunoblastic 9Hematologic Neoplasms 8Leukemia, Myeloid, Acute 7Neoplasms, Plasma Cell 6Neoplasms 6Myelodysplastic Syndromes 6Leukemia, Prolymphocytic 6Lymphoma, T-Cell 5Intraocular Lymphoma 5Leukemia, Hairy Cell 4Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, B-Cell 3

Interventions

Cyclophosphamide 7fludarabine phosphate 6fludarabine 5Immunotherapy, Adoptive 3blinatumomab 2Cytarabine 2Azacitidine 2AP 1903 reagent 2venetoclax 1tisagenlecleucel 1ruxolitinib 1relugolix 1pulrodemstat besilate 1niraparib 1nilotinib 1enzalutamide 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Rituximab 1Radiotherapy 1NKTR-255 1Melphalan 1Injections 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Cetuximab 1CTL019 chimeric antigen receptor 1CD3 Complex 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm, Residual × Rituximab × Clear all
NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Cedars-Sinai Medical Center

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡